John H. Alexander, MD, MHS on behalf of the APPRAISE-2 Investigators Apixaban with Antiplatelet Therapy After Acute Coronary Syndrome: Results of the APPRAISE-2.

Slides:



Advertisements
Similar presentations
John H. Alexander, MD, MHSc Duke Clinical Research Institute, Durham, NC, USA Lars Wallentin, MD, PhD Uppsala Clinical Research Center, Uppsala, Sweden.
Advertisements

Standard Medical Therapy TRA 40 mg mg/d TRA 40 mg mg/d Placebo EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc. 1  EP:CV Death/MI/stroke/hosp.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
The management of outpatients with stable coronary artery disease in clinical practice.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
lopidogrel in nstable Angina to Prevent ecurrent vents
Kenneth W. Mahaffey Daniel M. Wojdyla Stefan K. James Hugo A. Katus Steen Husted Gabriel Steg Christopher P. Cannon Richard C. Becker Claes Held Nardev.
Kenneth W. Mahaffey, Zhen Huang, Pierluigi Tricoci, Frans Van de Werf, Harvey D. White, Paul W. Armstrong, Claes Held, Sergio Leonardi, Philip E. Aylward,
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Objective, design and baseline Swedberg.
Results of the 1 st Phase of the International GLORIA-AF Registry Program: Regional Treatment Differences Before the Era of Novel Anticoagulants MV Huisman,
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
John H. Alexander, MD, MHS Associate Professor of Medicine Director, Cardiovascular Research Duke Clinical Research Institute Duke Medicine Update on antithrombotics.
S. Goto1, J. Zhu2, L. Lisheng2, BH. Oh3, D. Wojdyla4, M. Hanna5, J. Horowitz6, L. Wallentin7, D. Xavier8, JH. Alexander4 (1) Tokai University School of.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
1 HOT LINE PRESENTATION World Congress of Cardiology 2006 Barcelona, Spain September 5, 2006 Warfarin Antiplatelet Vascular Evaluation PAD Patients.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
THE MEDICINES COMPANY ® ® N = 9000 SA/NSTEMI/STEMI Maintenance Plavix PCI PLATFORM Screening Cangrelor infusion Placebo infusion PlavixPlacebo Plavix PCI.
(and r23-r35). A Phase 3 International, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety.
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
NSTE Acute Coronary Syndromes
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.
SS-1 Candesartan Support Slides. SS-2 Baseline Beta-Blocker Charm Added β-blocker Of patients on β-blockers Mean daily dose of β-blocker CandesartanPlacebo.
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D.,
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Gunter Breithardt,
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
C. Michael Gibson, M.S., M.D. Harvard Medical School
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS.
Rivaroxaban with or without aspirin in stable cardiovascular disease
For the HORIZONS-AMI Investigators
CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump
HOPE: Heart Outcomes Prevention Evaluation study
Oral Anticoagulation and Preventing Stent Thrombosis
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.
Dabigatran in myocardial injury after noncardiac surgery
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Dabigatran in myocardial injury after noncardiac surgery
Implications of Preoperative Thienopyridine Use
What oral antiplatelet therapy would you choose?
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
Dabigatran in myocardial injury after noncardiac surgery
Section C: Clinical trial update: Oral antiplatelet therapy
Presenter Disclosure Information
Stephan Windecker on behalf of the AUGUSTUS Investigators
Presentation transcript:

John H. Alexander, MD, MHS on behalf of the APPRAISE-2 Investigators Apixaban with Antiplatelet Therapy After Acute Coronary Syndrome: Results of the APPRAISE-2 Trial Sponsored by Bristol-Myers Squibb and Pfizer

Disclosures for John H. Alexander In compliance with AMA requirements, ISTH makes the following disclosures to the session audience: Research Support/P.I. Bristol-Myers Squibb, Pfizer, Merck-Schering Plough Employee No relevant conflicts of interest to declare Consultant Bristol-Myers Squibb, Pfizer, Polymedix Major Stockholder No relevant conflicts of interest to declare Speakers Bureau No relevant conflicts of interest to declare Honoraria No relevant conflicts of interest to declare Scientific Advisory Board Bristol-Myers Squibb, Regado Biosciences, Ortho-McNeil-Jannsen Presentation includes discussion of the following off-label use of a drug or medical device: Apixaban (Eliquis, Bristol-Myers Squibb)

Background Patients with ACS have recurrent ischemic events despite revascularization and antiplatelet therapy. Vitamin K antagonists have been shown to reduce recurrent events on a background of aspirin. Apixaban, an oral, direct, selective factor Xa inhibitor, reduces venous thromboembolism in patients undergoing orthopedic surgery and prevents thromboembolic events in patients with atrial fibrillation who are not candidates for oral vitamin K antagonists. The benefits of apixaban on a background of contemporary antiplatelet therapy following ACS are not known. Wallentin L. N Engl J Med 2009;361:1045–57. Andreotti F. Eur Heart J 2006 Mar;27:519–26. Hansen ML. Arch Intern Med 2010;170:1433–41. Wong PC. J Thromb Haemost 2008;6:820–9. Lassen MR. Lancet 2010;375:807–15. Lassen MR. N Engl J Med 2010;363:2487–98. Connolly SJ. N Engl J Med 2011;364:806–17.

APPRAISE-1 Trial Phase 2, 1715 patients, recent acute coronary syndrome Alexander JH. Circulation 2009;119:2877–85. Apixaban 2.5 mg BID, 10 mg QD, 10 mg BID, 20 mg QD, placebo Apixaban 10 mg BID & 20 mg QD stopped due to excess bleeding ISTH Major or CRNM Bleeding CV Death, MI, Stroke, Sev Recurrent Ischemia HR 2.45 ( ) p=0.005 HR: 0.61 ( ) p=0.07 HR: 0.73 ( ) p=0.21 HR 1.78 ( ) p=0.09

Apixaban 5 mg BID CrCl<40 ml/min 2.5 mg BID Primary Outcome: CV Death, MI, Ischemic Stroke Safety: TIMI Major Bleeding Randomize 1:1 Double blind Aspirin Other antiplatelet therapy N=10,800 Placebo Recent (≤7days) Acute Coronary Syndrome (STEMI or NSTE-ACS) At Least 2 Additional Risk-Factors Risk Factors Age ≥65 years Diabetes mellitus Prior MI within 5 years Cerebrovascular disease Peripheral vascular disease Clinical heart failure or LV EF <40% Renal dysfunction (CrCl <60 mL/min) No revascularization for ACS event Projected event rate: 8% / year, median f/u 1.25 years Event driven: 938 patients with the primary outcome 80% power to detect a 20% risk reduction at a one-sided α of % power to detect a 20% risk reduction at a one-sided α of Analysis: time to first event (stratified: single vs. dual antiplatelet therapy) Key subgroups: single / dual antiplatelet therapy, revascularized / not revascularized

Objective To determine whether apixaban 5mg twice daily reduces the composite of cardiovascular death, MI or stroke at an acceptable risk of bleeding in patients at high-risk for recurrent ischemic events receiving contemporary antiplatelet therapy following an acute coronary syndrome

Trial Stopped Prematurely On November 15, 2010 the Data Monitoring Committee recommended that the trial be stopped due to an excess of clinically important bleeding in the apixaban arm without a counterbalancing reduction in ischemic events. Patients = 7048 Median f/u = 3.5 months Primary Events = 412 (44%)

Enrollment 7392 patients, 858 sites, 39 countries Canada: 254 United States: 935 Mexico: 322 Finland: 7 Denmark: 71 Hungary: 241 Netherlands: 97 Ukraine: 258 Sweden: 105 Norway: 51 U.K.: 45 Belgium: 97 France: 40 Spain: 160 Austria: 114 Italy: 44 Israel: 139 Poland: 353 Czech Rep: 108 Chile: 56 Peru: 132 Colombia: 88 Brazil: 250 Argentina: 256 South Africa: 133 Russia: 1082 China: 75 India: 794 Korea: 177 Singapore: 25 Australia: 38 Germany: 160 Japan: 186 Romania: 158 Turkey: 20 Bulgaria: 202 Slovak Republic: 59 Switzerland: 38 New Zealand: 22

Baseline Characteristics Characteristic Apixaban (n=3705) Placebo (n=3687) Age, years67 (59, 73)67 (58, 74) Women, % Inclusion criteria risk factors, % Age > 65 y Diabetes mellitus MI within 5 years Cerebrovascular disease Peripheral vascular disease Heart failure or LVEF <40% Impaired renal function No revasc for index ACS event History of…, % Hypertension Revascularization

Index ACS Event Characteristic Apixaban (n=3705) Placebo (n=3687) Time from index ACS event to rand, days 6.0 (4.0, 7.0) Elevated biomarkers (CKMB or Troponin)81.2 Index ACS event type ST-elevation MI Non-ST-elevation MI Unstable angina Index event ACS management Coronary angiography PCI CABG0.6 Medical therapy only Dual antiplatelet therapy

Primary Outcome CV Death, MI, Ischemic Stroke Apixaban279 (7.5%) Placebo293 (7.9%) HR 0.95; 95% CI ; p=0.509

Other Efficacy Outcomes Apixaban N=3705 Placebo N=3687 p-value CV death, MI, ischemic stroke CV death, MI, ischemic stroke, UA Death CV death Myocardial infarction Ischemic stroke Unstable angina Definite stent thrombosis

Primary Outcome CV Death, MI, Stroke — Subgroups *HR not calculated for subgroups with ≤10 events

TIMI Major Bleeding Apixaban 48 (1.3%) Placebo 18 (0.5%) HR 2.59; 95% CI 1.50–4.46; p=0.001

Other Bleeding Scales Apixaban N=3705 Placebo N=3687 p-value TIMI major TIMI major or minor <0.001 ISTH major2.71.1<0.001 ISTH major or clinically relevant non-major <0.001 GUSTO severe Intracranial Fatal bleeding: Apixaban = 5 vs. Placebo = 0 ISTH major bleeding = bleeding leading to death, occurring in a critical location, or associated with a ≥2 g/dL drop in hemoglobin or transfusion of 2 or more units of PRBC.

TIMI Major Bleeding Subgroups *HR not calculated for subgroups with ≤10 events

Conclusions APPRAISE-2 Summary: The addition of apixaban to contemporary antiplatelet therapy increases major bleeding without any significant reduction in ischemic events in high-risk patients following an ACS. Limitations: Because of the early termination of the trial, with accrual of two-thirds of the expected events and a median follow-up of 8 months, some uncertainty regarding efficacy remains. Clinical Implications: The addition of an anticoagulant to currently recommended anti-platelet treatment post-ACS should be used cautiously and only in patients with clear indications for both an anticoagulant and antiplatelet therapy. Future Directions: Further research is needed to explore different antithrombotic combinations and doses that might have a different risk-benefit balance.

Acknowledgement Executive Committee: RA Harrington (co-chair), L Wallentin (co-chair), JH Alexander (PI), S James (co-PI), RD Lopes (CEC chair), P Mohan and D Liaw (BMS). Steering Committee: R Diaz, J Amerena, K Huber, F Cools, J Nicolau, D Raev, S Goodman, R Corbalan, Y Huo, M Urina-Triana, P Jansky, S Husted, K Niemela, G Montalescot, H Darius, M Keltai,; P Pais, B Lewis, R De Caterina, H Ogawa, SJ Park, JL Leiva-Pons, J Cornel, F Verheugt, H White, D Atar, A Gallegos-Cazorla, W Ramos, W Ruzyllo, D Vinereanu, M Ruda, RS Tan, V Fridrich, H Du Truit Theron, J Lopez-Sendon, T Jernberg, T Luscher, C Erol, M Flather, A Parkhomenko, D Bhatt, J Miller. Data Monitoring Committee: M Simoons (chair), P Armstrong, J DeLemos, T Kimura, A Maggioni, S Pocock. CEC: R Lopes, K Mahaffey, S Al-Khatib, A Hernandez, B Kolls, S Leonardi, R Mehta, C Melloni, LK Newby, M Roe, B Shah, L Szczech, P Tricoci, A Truffa, J Vavalle, AB Cavalcanti, L Echenique, C Gonzaga, HP Guimaraes, L Armaganijan. DCRI: L Hatch, M Banks, A Handler, L Perkins, A Heath, Y Lokhnygina, S Dickerson, A Stone, K Lee, J Garg. BMS / Pfizer: D Liaw, P Mohan, M Hanna, F Fiedorek, JM Bocquet, N Kolivodiakos, L Rossi, R Braceras, H Pouleur, N Jackson, D Hessinger. PPD: V Ponder-Lee, K Griffith, T Dremsizov, A Bevan, C Murphy, M Okabe, J Knoll, A Burr. The APPRAISE-2 Investigators, Coordinators and Patients

APPRAISE-2 Publication

Thank you to our hosts. Congratulations to the Soccer World Cup Champions!